logo
TEVAR procedure performed by cardiologists saves elderly man in Madurai hospital

TEVAR procedure performed by cardiologists saves elderly man in Madurai hospital

The Hindu19-06-2025
A 70-year-old man, who was suffering from a life threatening bulge in the major artery of his chest - a thoracic aortic aneurysm - was successfully treated by a team of surgeons at the Meenakshi Super Speciality Hospital.
Addressing a press conference here on Wednesday, cardiologist Sivakumar and team members said that the patient was in cardiogenic shock, a critical condition where the heart is unable to pump enough blood. A CT aortogram revealed that the aneurysm had ruptured into the oesophagus, making the situation extremely grave, he said.
The doctors performed a minimally invasive procedure called Thoracic Endovascular Aortic Repair (TEVAR), placing a stent graft inside the damaged artery through a small puncture in the leg. The rupture was immediately sealed, leading to a remarkable recovery. The patient's blood pressure and kidney function improved significantly, and he was discharged with medication and is now doing well under close follow-up.
In another patient, using the Transcatheter Aortic Valve Replacement (TAVR), a non-surgical method of replacing a severely narrowed aortic valve through a catheter-based approach, the team of surgeons successfully treated a 68-year-old man.
The patient had severe narrowing of the aortic valve (aortic stenosis) and was admitted with congestive cardiac failure (CCF). He had biventricular dysfunction with a reduced heart pumping capacity (ejection fraction of 35%), kidney failure (AKI), ascites, and pulmonary hypertension.
After evaluation and stabilisation with dialysis, the team performed TAVR, replacing the diseased valve through a small puncture in the groin. Once the new valve began to function, the patient showed rapid improvement in heart and kidney function. His liver condition also began to stabilise, and he was discharged in a stable condition.
In recent times, the hospital had successfully performed Transcatheter Edge-to-Edge Repair (TEER), a technique that clips the leaking mitral valve to reduce mitral regurgitation without the need for open-heart surgery, for a 41-year-old male, Dr. Sivakumar added.
Before the advent of structural interventions, surgeons had to do open-heart surgery, stopping the heart, and using a heart-lung machine to fix or replace valves or walls. Recovery was long and riskier. Today, these advances allow surgeons to treat heart problems through blood vessels using advanced imaging and tiny tools. The procedures offer faster recovery, less pain and new hope for elderly or high-risk patients who couldn't undergo traditional surgery.
These high-risk structural interventions were performed by a multidisciplinary team including S. Selvamani, N. Ganesan, M. Sampath Kumar, Jeyapandiyan, Thomas Xavier, S. Kumar, R.M. Krishnan, Rajan, and Prabhu Kumarappan Chidambaram.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ADIA to Invest USD 200 Million in Meril
ADIA to Invest USD 200 Million in Meril

Mint

time21-07-2025

  • Mint

ADIA to Invest USD 200 Million in Meril

Vapi, India– [21 July 2025] – A wholly owned subsidiary of the Abu Dhabi Investment Authority ('ADIA') has entered into definitive agreements to invest USD 200 million for a ~3% stake in Micro Life Sciences Private Limited ('Meril'), one of India's leading medical devices companies. This investment values Meril at an enterprise value of USD 6.6 billion. The transaction is subject to regulatory approval by the Competition Commission of India (CCI). Post this investment, Meril will be backed by two globally recognized investors, ADIA and Warburg Pincus. Founded by the Bilakhia Group, Meril is a global innovator in medical technology (MedTech), with a strong focus on clinically advanced solutions across multiple specialties — including Cardiovascular, Structural Heart, Orthopaedics, Endo-surgery, In-vitro Diagnostics and Surgical Robotics. Headquartered in Vapi, India, Meril operates state-of-the-art, vertically integrated, and globally certified manufacturing and R&D facilities, across a 100 acre sustainable MedTech campus. The company employs more than 13,000 people, has 35+ global subsidiaries, and serves healthcare systems in 150+ countries. Meril is committed to becoming the world's leading MedTech company, powered 100% by green energy, reinforcing its commitment to sustainable innovation. Meril With a robust in-house global R&D ecosystem and a portfolio of 200+ technology platforms, Meril continues to lead in global clinical research and education. Breakthrough innovations such as the Myval Transcatheter Heart Valve (THV) series, MyClip Transcatheter Edge-to-Edge Repair (TEER) system, and the MISSO Surgical Robotic System highlight Meril's dedication to next-generation innovation. Through its 12+ global training academies, Meril empowers over 10,000 healthcare professionals annually. Sanjeev Bhatt, Senior Vice President – Strategy, Meril said: 'This investment by ADIA reinforces confidence in Meril's long term vision and global ambitions. This investment will enable us to accelerate growth, attract world-class talent, and further strengthen our R&D and clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions.' Meril is a global medical technology company headquartered in Vapi, India. With a strong emphasis on innovation, Meril develops clinically meaningful products aimed at enhancing patient outcomes across cardiovascular, orthopaedic, diagnostic, Endo Surgery and robotic surgery domains. Founded by the Bilakhia Group, the company is committed to sustainability, quality, and global impact. For more information: About Abu Dhabi Investment Authority (ADIA) Established in 1976, the Abu Dhabi Investment Authority ('ADIA') is a globally-diversified investment institution that prudently invests funds on behalf of the Government of Abu Dhabi through a strategy focused on long-term value creation. For more information: Media contact :media@ Note to readers: This article is part of Mint's paid consumer connect Initiative. Mint assumes no editorial involvement or responsibility for errors, omissions, or content accuracy. Want to get your story featured as above?click here!

ADIA to Invest USD 200 Million in Meril
ADIA to Invest USD 200 Million in Meril

Hans India

time21-07-2025

  • Hans India

ADIA to Invest USD 200 Million in Meril

Vapi -- A wholly owned subsidiary of the Abu Dhabi Investment Authority ('ADIA') has entered into definitive agreements to invest USD 200 million for ~3% stake in Micro Life Sciences Private Limited ('Meril'), one of India's leading medical devices companies. This investment values Meril at an enterprise value of USD 6.6 billion. The transaction is subject to regulatory approval by the Competition Commission of India (CCI). Post this investment, Meril will be backed by two globally recognized investors, ADIA and Warburg Pincus. Founded by the Bilakhia Group, Meril is a global innovator in medical technology (MedTech), with a strong focus on clinically advanced solutions across multiple specialties — including Cardiovascular, Structural Heart, Orthopaedics, Endo-surgery, In-vitro Diagnostics and Surgical Robotics. Headquartered in Vapi, India, Meril operates state-of-the-art, vertically integrated, and globally certified manufacturing and R&D facilities, across a 100-acre sustainable MedTech campus. The company employs more than 13,000 people, has 35+ global subsidiaries, and serves healthcare systems in 150+ countries. Meril is committed to becoming the world's leading MedTech company, powered 100% by green energy, reinforcing its commitment to sustainable innovation. With a robust in-house global R&D ecosystem and a portfolio of 200+ technology platforms, Meril continues to lead in global clinical research and education. Breakthrough innovations such as the Myval Transcatheter Heart Valve (THV) series, MyClip Transcatheter Edge-to-Edge Repair (TEER) system, and the MISSO Surgical Robotic System highlight Meril's dedication to next-generation innovation. Through its 12+ global training academies, Meril empowers over 10,000 healthcare professionals annually. Sanjeev Bhatt, Senior Vice President – Strategy, Meril said: 'This investment by ADIA reinforces confidence in Meril's long term vision and global ambitions. This investment will enable us to accelerate growth, attract world-class talent, and further strengthen our RCD and clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions.'

ADIA to Invest USD 200 Million in Meril
ADIA to Invest USD 200 Million in Meril

Fashion Value Chain

time20-07-2025

  • Fashion Value Chain

ADIA to Invest USD 200 Million in Meril

A wholly owned subsidiary of the Abu Dhabi Investment Authority ('ADIA') has entered into definitive agreements to invest USD 200 million for a ~3% stake in Micro Life Sciences Private Limited ('Meril'), one of India's leading medical devices companies. This investment values Meril at an enterprise value of USD 6.6 billion. The transaction is subject to regulatory approval by the Competition Commission of India (CCI). Post this investment, Meril will be backed by two globally recognized investors, ADIA and Warburg Pincus. ADIA to invest USD 200 million in Meril, valuing the Indian medical devices company at an enterprise value of USD 6.6 billion Founded by the Bilakhia Group, Meril is a global innovator in medical technology (MedTech), with a strong focus on clinically advanced solutions across multiple specialties – including Cardiovascular, Structural Heart, Orthopaedics, Endo-surgery, In-vitro Diagnostics and Surgical Robotics. Headquartered in Vapi, India, Meril operates state-of-the-art, vertically integrated, and globally certified manufacturing and RCD facilities, across a 100 acre sustainable MedTech campus. The company employs more than 13,000 people, has 35+ global subsidiaries, and serves healthcare systems in 150+ countries. Meril is committed to becoming the world's leading MedTech company, powered 100% by green energy, reinforcing its commitment to sustainable innovation. With a robust in-house global RCD ecosystem and a portfolio of 200+ technology platforms, Meril continues to lead in global clinical research and education. Breakthrough innovations such as the Myval Transcatheter Heart Valve (THV) series, MyClip Transcatheter Edge-to-Edge Repair (TEER) system, and the MISSO Surgical Robotic System highlight Meril's dedication to next-generation innovation. Through its 12+ global training academies, Meril empowers over 10,000 healthcare professionals annually. Sanjeev Bhatt, Senior Vice President – Strategy, Meril said: 'This investment by ADIA reinforces confidence in Meril's long term vision and global ambitions. This investment will enable us to accelerate growth, attract world-class talent, and further strengthen our RCD and clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store